Page 1571 - Williams Hematology ( PDFDrive )

1546 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1547

146. Lai R, O’Brien S, Maushouri T, et al: Prognostic value of plasma interleukin-6 levels in 177. Cohen RB, Abdallah JM, Gray JR, et al: Reversible neurologic toxicity in patients
patients with chronic lymphocytic leukemia. Cancer 95:1071–1075, 2002. treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic
147. Wierda WG, Johnson MM, Do KA, et al: Plasma interleukin 8 level predicts for survival lymphocytic leukemia. Ann Intern Med 118:114–116, 1993.
in chronic lymphocytic leukaemia. Br J Haematol 120:452–456, 2003. 178. Tosti S, Caruso R, D’Adamo F, et al: Severe autoimmune hemolytic anemia in a patient
148. Cimmino A, Calin GA, Fabbri M, et al: MiR-15 and miR-16 induce apoptosis by target- with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann
ing BCL2. Proc Natl Acad Sci U S A 102:13944–13949, 2005. Hematol 65:238–239, 1992.
149. Fabbri M, Bottoni A, Shimizu M, et al: Association of a microRNA/TP53 feedback cir- 179. Bastion Y, Coiffier B, Dumontet C, et al: Severe autoimmune hemolytic anemia in two
cuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 3:171–
305:59–67, 2011. 172, 1992.
150. Moussay E, Palissot V, Vallar L, et al: Determination of genes and microRNAs involved 180. Vick DJ, Byrd JC, Beal CL, et al: Mixed-type autoimmune hemolytic anemia following
in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lym-
9:115, 2010. phoma. Vox Sang 74:122–126, 1998.
151. Visone R, Rassenti LZ, Veronese A, et al: Karyotype-specific microRNA signature in 181. Kielstein JT, Stadler M, Czock D, et al: Dialysate concentration and pharmacokinetics
chronic lymphocytic leukemia. Blood 114:3872–3879, 2009. of 2F-Ara-A in a patient with acute renal failure. Eur J Haematol 74:533–534, 2005.
152. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leuke- 182. Byrd JC, Peterson B, Piro L, et al: A phase II study of cladribine treatment for fludara-
mia. Blood 46:219–234, 1975. bine refractory B cell chronic lymphocytic leukemia: Results from CALGB Study 9211.
153. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lym- Leukemia 17:323–327, 2003.
phocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206, 183. Sauter C, Lamanna N, Weiss MA: Pentostatin in chronic lymphocytic leukemia. Expert
1981. Opin Drug Metab Toxicol 4:1217–1222, 2008.
154. Vasconcelos Y, Davi F, Levy V, et al: Binet’s staging system and VH genes are indepen- 184. Ho AD, Thaler J, Stryckmans P, et al: Pentostatin in refractory chronic lymphocytic
dent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin leukemia: A phase II trial of the European Organization for Research and Treatment of
Oncol 21:3928–3932, 2003. Cancer. J Natl Cancer Inst 82:1416–1420, 1990.
155. Montserrat E, Marques-Pereira JP, Gallart MT, et al: Bone marrow histopathologic 185. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukemia: A
patterns and immunologic findings in B-chronic lymphocytic leukemia. Cancer 54: phase II trial of Cancer and Leukemia group B. J Clin Oncol 7:433–438, 1989.
447–451, 1984. 186. Mulligan SP, Karlsson K, Stromberg M, et al: Cladribine prolongs progression-free sur-
156. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al: Detection of Richter’s transformation vival and time to second treatment compared to fludarabine and high-dose chlorambu-
of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47:1267–1273, 2006. cil in chronic lymphocytic leukemia. Leuk Lymphoma 55:2769–2777, 2014.
157. Falchi L, Keating MJ, Marom EM, et al: Correlation between FDG/PET, histology, 187. Tsimberidou AM, Wierda WG, Plunkett W, et al: Phase I-II study of oxaliplatin, flu-
characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood darabine, cytarabine, and rituximab combination therapy in patients with Richter’s
123:2783–2790, 2014. syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26:
158. Pflug N, Bahlo J, Shanafelt TD, et al: Development of a comprehensive prognostic index 196–203, 2008.
for patients with chronic lymphocytic leukemia. Blood 124:49–62, 2014. 188. Robertson LE, Hall R, Keating MJ, et al: High-dose cytosine arabinoside in chronic
159. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the ran- lymphocytic leukemia: A clinical and pharmacologic analysis. Leuk Lymphoma 10:
domized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst 91:861–868, 1999. 43–48, 1993.
160. Dighiero G, Maloum K, Desablens B, et al: Chlorambucil in indolent chronic lympho- 189. Raphael B, Andersen JW, Silber R, et al: Comparison of chlorambucil and prednisone
cytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic
J Med 338:1506–1514, 1998. lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology
161. Burgman MA, Busch R, Eichhorst B, et al: Overall survival in early stage chronic Group randomized clinical trial. J Clin Oncol 9:770–776, 1991.
lymphocytic leukemia patients with treatment indication due to disease progression: 190. Montserrat E, Alcala A, Alonso C, et al: A randomized trial comparing chlorambucil
Follow-Up Data of the CLL1 Trial of the German CLL Study Group (GCLLSG). Blood plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of
122 (21), 2013. chronic lymphocytic leukemia stages B and C. Nouv Rev Fr Hematol 30:429–432, 1988.
162. Eichhorst B, Goede V, Hallek M: Treatment of elderly patients with chronic lympho- 191. Prognostic and therapeutic advances in CLL management: The experience of the French
cytic leukemia. Leuk Lymphoma 50:171–178, 2009. Cooperative Group. French Cooperative Group on Chronic Lymphocytic Leukemia.
163. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as Semin Hematol 24:275–290, 1987.
primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757, 2000. 192. Friedenberg WR, Anderson J, Wolf BC, et al: Modified vincristine, doxorubicin, and
164. Knospe WH, Loeb V Jr, Huguley CM Jr: Proceedings: Bi-weekly chlorambucil treat- dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic
ment of chronic lymphocytic leukemia. Cancer 33:555–562, 1974. leukemia. An Eastern Cooperative Oncology Group study. Cancer 71:2983–2989, 1993.
165. Sawitsky A, Rai KR, Glidewell O, et al: Comparison of daily versus intermittent chlo- 193. Keating MJ, O’Brien S, Lerner S, et al: Long-term follow-up of patients with chronic
rambucil and prednisone therapy in the treatment of patients with chronic lymphocytic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood
leukemia. Blood 50:1049–1059, 1977. 92:1165–1171, 1998.
166. Huguley CM Jr: Treatment of chronic lymphocytic leukemia. Cancer Treat Rev 4: 194. Elias L, Stock-Novack D, Head DR, et al: A phase I trial of combination fludarabine
261–273, 1977. monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest
167. Shaklai S, Bairey O, Blickstein D, et al: Severe myelotoxicity of oral etoposide in heav- Oncology Group study. Leukemia 7:361–365, 1993.
ily pretreated patients with non-Hodgkin’s lymphoma or chronic lymphatic leukemia. 195. O’Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophos-
Cancer 77:2313–2317, 1996. phamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:
168. Robak T, Szmigielska-Kaplon A, Blonski JZ, et al: Activity of cladribine combined 1414–1420, 2001.
with etoposide in heavily pretreated patients with indolent lymphoid malignancies. 196. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus
Chemotherapy 51:247–251, 2005. fludarabine alone in first-line therapy of younger patients with chronic lymphocytic
169. Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamus- leukemia. Blood 107:885–891, 2006.
tine compared with chlorambucil in previously untreated patients with chronic lym- 197. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophos-
phocytic leukemia. J Clin Oncol 27:4378–4384, 2009. phamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial):
170. Leoni LM, Bailey B, Reifert J, et al: Bendamustine (Treanda) displays a distinct pattern A randomised controlled trial. Lancet 370:230–239, 2007.
of cytotoxicity and unique mechanistic features compared with other alkylating agents. 198. Robak T, Blonski JZ, Kasznicki M, et al: Cladribine with prednisone versus chlorambu-
Clin Cancer Res 14:309–317, 2008. cil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a
171. Traynor K: Treanda approved for chronic lymphocytic leukemia. Am J Health Syst prospective, randomized, multicenter trial. Blood 96:2723–2729, 2000.
Pharm 65:793, 2008. 199. Robak T, Blonski JZ, Kasznicki M, et al: Comparison of cladribine plus prednisone with
172. O’Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final
in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit 11:PI71–9,
prognostic model for response to treatment. Blood 82:1695–1700, 1993. 2005.
173. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of flu- 200. Laurencet F, Ballabeni P, Rufener B, et al: The multicenter trial SAKK 37/95 of cladrib-
darabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment ine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leuke-
of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on mias and low-grade non-Hodgkin’s lymphomas. Acta Haematol 117:40–47, 2007.
CLL. Lancet 347:1432–1438, 1996. 201. Tefferi A, Li CY, Reeder CB, et al: A phase II study of sequential combination chemo-
174. Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine com- therapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previ-
pared with chlorambucil does not result in a major benefit for elderly patients with ously untreated patients with chronic lymphocytic leukemia. Leukemia 15:1171–1175,
advanced chronic lymphocytic leukemia. Blood 114:3382–3391, 2009. 2001.
175. Wijermans PW, Gerrits WB, Haak HL: Severe immunodeficiency in patients treated 202. Robak T, Blonski JZ, Wawrzyniak E, et al: Activity of cladribine combined with cyclo-
with fludarabine monophosphate. Eur J Haematol 50:292–296, 1993. phosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/
176. Bergmann L, Fenchel K, Jahn B, et al: Immunosuppressive effects and clinical response TP53 deletion: Report from the Polish Adult Leukemia Group. Cancer 115:94–100,
of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4:371–375, 1993. 2009.

Kaushansky_chapter 92_p1527-1552.indd 1546 9/18/15 10:49 AM